Detection of RAS and RAS-associated alterations in primary lung adenocarcinomas. A correlation between molecular findings and tumor characteristics

Irfan Shaukat, Jason J. Kern, Naseruddin Höti, Hui Zhang, Jason Li, Gang Zheng, Frederic B Askin, Edward Gabrielson, Qing Kay Li

Research output: Contribution to journalArticle

Abstract

Rat sarcoma (RAS) and RAS-associated pathways play important roles in the pathogenesis of lung cancers and in the development of targeted therapies. However, the clinical significance of RAS pathways is still not fully understood. We investigated the RAS-associated molecular aberrations in primary lung adenocarcinomas and correlated molecular findings with clinicopathological characteristics of tumors. A total of 220 surgically resected tumors were identified for which a lung cancer molecular panel (testing 7 genes by next-generation sequencing and 3 genes for rearrangement by fluorescence in situ hybridization) had been performed. The overall molecular alterations were detected in 143 cases (65.00%), including 58 cases (26.36%) of KRAS, 40 cases (18.18%) of EGFR, 24 cases (10.91%) of BRAF, 8 cases (3.64%) of PIK3CA, 7 cases (3.18%) of NRAS, 6 cases (2.73%) of ALK alterations. KRAS, BRAF, NRAS, and PIK3CA mutations were more commonly seen in smokers and occurred with much higher rates than previously published data. BRAFV600E mutations were commonly seen in female smokers, whereas, BRAFnon-V600E mutations were seen in both male and female smokers with moderately to poorly differentiated tumors. PIK3CA mutations were predominantly occurred in p.E545K and p.E542K on exon 9 in moderately to poorly differentiated tumors.

LanguageEnglish (US)
Pages18-25
Number of pages8
JournalHuman pathology
Volume84
DOIs
StatePublished - Feb 1 2019

Fingerprint

Non-Small Cell Lung Carcinoma
Sarcoma
Mutation
Lung Neoplasms
Neoplasms
Gene Rearrangement
Fluorescence In Situ Hybridization
Exons
Adenocarcinoma of lung
Genes
Therapeutics

Keywords

  • EGFR
  • KRAS
  • Lung adenocarcinomas (ADC)
  • Non–small cell lung carcinoma (NSCLC)
  • NRAS
  • RAS mutations
  • Targeted therapy

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Detection of RAS and RAS-associated alterations in primary lung adenocarcinomas. A correlation between molecular findings and tumor characteristics. / Shaukat, Irfan; Kern, Jason J.; Höti, Naseruddin; Zhang, Hui; Li, Jason; Zheng, Gang; Askin, Frederic B; Gabrielson, Edward; Li, Qing Kay.

In: Human pathology, Vol. 84, 01.02.2019, p. 18-25.

Research output: Contribution to journalArticle

@article{8a001a2be55e471eac33e956413b427e,
title = "Detection of RAS and RAS-associated alterations in primary lung adenocarcinomas. A correlation between molecular findings and tumor characteristics",
abstract = "Rat sarcoma (RAS) and RAS-associated pathways play important roles in the pathogenesis of lung cancers and in the development of targeted therapies. However, the clinical significance of RAS pathways is still not fully understood. We investigated the RAS-associated molecular aberrations in primary lung adenocarcinomas and correlated molecular findings with clinicopathological characteristics of tumors. A total of 220 surgically resected tumors were identified for which a lung cancer molecular panel (testing 7 genes by next-generation sequencing and 3 genes for rearrangement by fluorescence in situ hybridization) had been performed. The overall molecular alterations were detected in 143 cases (65.00{\%}), including 58 cases (26.36{\%}) of KRAS, 40 cases (18.18{\%}) of EGFR, 24 cases (10.91{\%}) of BRAF, 8 cases (3.64{\%}) of PIK3CA, 7 cases (3.18{\%}) of NRAS, 6 cases (2.73{\%}) of ALK alterations. KRAS, BRAF, NRAS, and PIK3CA mutations were more commonly seen in smokers and occurred with much higher rates than previously published data. BRAFV600E mutations were commonly seen in female smokers, whereas, BRAFnon-V600E mutations were seen in both male and female smokers with moderately to poorly differentiated tumors. PIK3CA mutations were predominantly occurred in p.E545K and p.E542K on exon 9 in moderately to poorly differentiated tumors.",
keywords = "EGFR, KRAS, Lung adenocarcinomas (ADC), Non–small cell lung carcinoma (NSCLC), NRAS, RAS mutations, Targeted therapy",
author = "Irfan Shaukat and Kern, {Jason J.} and Naseruddin H{\"o}ti and Hui Zhang and Jason Li and Gang Zheng and Askin, {Frederic B} and Edward Gabrielson and Li, {Qing Kay}",
year = "2019",
month = "2",
day = "1",
doi = "10.1016/j.humpath.2018.09.004",
language = "English (US)",
volume = "84",
pages = "18--25",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Detection of RAS and RAS-associated alterations in primary lung adenocarcinomas. A correlation between molecular findings and tumor characteristics

AU - Shaukat, Irfan

AU - Kern, Jason J.

AU - Höti, Naseruddin

AU - Zhang, Hui

AU - Li, Jason

AU - Zheng, Gang

AU - Askin, Frederic B

AU - Gabrielson, Edward

AU - Li, Qing Kay

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Rat sarcoma (RAS) and RAS-associated pathways play important roles in the pathogenesis of lung cancers and in the development of targeted therapies. However, the clinical significance of RAS pathways is still not fully understood. We investigated the RAS-associated molecular aberrations in primary lung adenocarcinomas and correlated molecular findings with clinicopathological characteristics of tumors. A total of 220 surgically resected tumors were identified for which a lung cancer molecular panel (testing 7 genes by next-generation sequencing and 3 genes for rearrangement by fluorescence in situ hybridization) had been performed. The overall molecular alterations were detected in 143 cases (65.00%), including 58 cases (26.36%) of KRAS, 40 cases (18.18%) of EGFR, 24 cases (10.91%) of BRAF, 8 cases (3.64%) of PIK3CA, 7 cases (3.18%) of NRAS, 6 cases (2.73%) of ALK alterations. KRAS, BRAF, NRAS, and PIK3CA mutations were more commonly seen in smokers and occurred with much higher rates than previously published data. BRAFV600E mutations were commonly seen in female smokers, whereas, BRAFnon-V600E mutations were seen in both male and female smokers with moderately to poorly differentiated tumors. PIK3CA mutations were predominantly occurred in p.E545K and p.E542K on exon 9 in moderately to poorly differentiated tumors.

AB - Rat sarcoma (RAS) and RAS-associated pathways play important roles in the pathogenesis of lung cancers and in the development of targeted therapies. However, the clinical significance of RAS pathways is still not fully understood. We investigated the RAS-associated molecular aberrations in primary lung adenocarcinomas and correlated molecular findings with clinicopathological characteristics of tumors. A total of 220 surgically resected tumors were identified for which a lung cancer molecular panel (testing 7 genes by next-generation sequencing and 3 genes for rearrangement by fluorescence in situ hybridization) had been performed. The overall molecular alterations were detected in 143 cases (65.00%), including 58 cases (26.36%) of KRAS, 40 cases (18.18%) of EGFR, 24 cases (10.91%) of BRAF, 8 cases (3.64%) of PIK3CA, 7 cases (3.18%) of NRAS, 6 cases (2.73%) of ALK alterations. KRAS, BRAF, NRAS, and PIK3CA mutations were more commonly seen in smokers and occurred with much higher rates than previously published data. BRAFV600E mutations were commonly seen in female smokers, whereas, BRAFnon-V600E mutations were seen in both male and female smokers with moderately to poorly differentiated tumors. PIK3CA mutations were predominantly occurred in p.E545K and p.E542K on exon 9 in moderately to poorly differentiated tumors.

KW - EGFR

KW - KRAS

KW - Lung adenocarcinomas (ADC)

KW - Non–small cell lung carcinoma (NSCLC)

KW - NRAS

KW - RAS mutations

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85058230141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058230141&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2018.09.004

DO - 10.1016/j.humpath.2018.09.004

M3 - Article

VL - 84

SP - 18

EP - 25

JO - Human Pathology

T2 - Human Pathology

JF - Human Pathology

SN - 0046-8177

ER -